Cannabis Science, Inc. (OTCBB: CBIS.OB - News), a pioneering US biotech
company developing pharmaceutical cannabis products, is pleased to announce that
it has signed a major multi-company acquisition agreement that will boost
revenues, strengthen pharmaceutical operations and our management team.
These additions will enhance our internal operations and help to fast track
our full line of Cannabis Science Brand pharmaceutical and over the counter
products through multiple distribution channels to be made
available nationally. Over the coming days there will be several
announcements outlining the outstanding growth opportunities that will be
enhanced by these deals.
Cannabis Science Inc., President & CEO, Dr Robert Melamede Ph.D., stated,
“These deals put Cannabis Science in a very strong position to grow our Company
quickly. We have increased our corporate structure to handle the impressive
growth opportunities that are unfolding before us. We have already begun a
limited production of the Cannabis Science brand product line with their
successful therapeutic functionality demonstrated by the case studies of cancer
patients that are posted on the Cannabis Science homepage (http://www.cannabisscience.com).
It has taken time and effort to develop many important relationships, the
first of which are now coming to fruition. These advancements will take Cannabis
Science to the next level with multiple products that will have multiple
distribution channels nationwide. These deals include strategic relationships
with pharmacists and the exclusive production of organically grown strains for
our scientific medicinal formulations. Additional accessory businesses will
include laboratory capacity for product quality assurance and testing, and
educational platforms to produce and distribute information about the science of
cannabis that will further our cause through education.”
The main elements of this group of deals are the following:
1. New Executive Management Appointments
2. Licensing agreement for exclusive strains, lab facilities, and commercial
3. A “Cannabis University” acquisition to be converted to Cannabis Science
4. New Cannabis Science Brand product lines
5. Multiple national product distribution channels
6. Focused continued growth plan based on operational expertise and market
7. Critical ailment target expansions
Apothecary Genetics, a cannabis seed breeding company signed a licensing
agreement with Cannabis Science. Apothecary will produce several Cannabis
Science Brand Formulations for the California medical cannabis market. As well,
Apothecary will provide research and development facilities with full circle
operations including a California laboratory facility for internal research and
development, along with 16 unique genetic strains specifically generated and
maintained by a cancer survivor who recognizes the importance of proper growth
GGECO University, an online video-based medical cannabis education system,
offering courses dealing with medical cannabis law, the benefits of medical
marijuana, cooking, horticulture, and bud tending, has been acquired by Cannabis
Science, following the university‘s name to Cannabis Science University.
Cannabis Science hopes to use this platform to educate the general public,
patients, and even those who have already been involved in the medical cannabis
industry on the medical benefits of cannabis, how it is grown, how to use it
safely, and the many applications or ways to administer the medication.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical
marijuana research and development. The second formulations will address the
needs of patients choosing to use concentrated cannabis extracts to treat their
ailments. Eventually, all Americans will have access to a safe and effective FDA
approved medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is scientifically
absurd. Cannabis medicines, with no effective lethal dose, are far safer than
aspirin, acetaminophen, and most other OTC drugs that kill thousands of
Americans every year.
The Company works with world authorities on phytocannabinoid science
targeting critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based pharmaceutical
products. In sum, we are dedicated to the creation of cannabis-based medicines,
both with and without psychoactive properties, to treat disease and the symptoms
of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act
of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur. Factors that
could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to update the
results of these forward-looking statements.